Imaging in cystic fibrosis and non-cystic fibrosis bronchiectasis.

Semin Respir Crit Care Med

Department of Radiology, St. Vincent's University Hospital, Elm Park, Dublin, Ireland.

Published: April 2015

Bronchiectasis is defined as a permanent and progressive dilation of the airways, typically as a result of inflammation, infection, and subsequent repair. It typically presents with chronic cough, suppurative sputum production, and airway dilation. High-resolution computed tomography (HRCT) is now well established as the primary imaging tool for its investigation. Cystic fibrosis (CF) remains the most common autosomal recessive inherited disorder worldwide and its pulmonary hallmark is bronchiectasis. Although CF and non-CF bronchiectasis are different clinical entities, they are typically imaged using HRCT and share many imaging aspects, and also some differences. Several important recent CT technology developments have improved the detection and characterization of bronchiectasis and its complications. Many CT aspects of radiation exposure have also undergone important enhancements in recent years resulting in significant dose reductions. This is particularly relevant in a pulmonary disease such as bronchiectasis, which often undergoes serial HRCT surveillance in contemporary practice. Several new CT clinical applications in bronchiectasis have been recently advanced, and CT is now being increasingly incorporated into investigative algorithms to assess bronchiectasis treatment effects. In this review, we assess the latest imaging features of CF and non-CF bronchiectasis, discuss radiation dose reducing methods and technology of the latest scanners, describe recent CT clinical applications, and explore the use of CT as a treatment surrogate in CF and non-CF bronchiectasis.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0035-1546749DOI Listing

Publication Analysis

Top Keywords

non-cf bronchiectasis
12
bronchiectasis
10
cystic fibrosis
8
clinical applications
8
imaging
4
imaging cystic
4
fibrosis non-cystic
4
non-cystic fibrosis
4
fibrosis bronchiectasis
4
bronchiectasis bronchiectasis
4

Similar Publications

Reconsidering the Diagnosis: Abnormal Sweat Chloride Tests in Non-CF Bronchiectasis.

Pediatr Pulmonol

January 2025

Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, Virginia, USA.

Introduction: While the diagnosis of cystic fibrosis (CF) is often straightforward and reliant on correlation between genetic testing and clinical signs and symptoms, there is a subset where the distinction is not nearly as clearcut. This has previously been reported in patients identified through newborn screening but not meeting full CF diagnostic criteria, earning the label of CF Screen Positive, Inconclusive Diagnosis (CFSPID) instead. A homologous diagnostic category in adults is named CF Transmembrane Conductance Regulator-Related Disorder (CFTR-RD).

View Article and Find Full Text PDF

Background: Non-cystic fibrosis (non-CF) bronchiectasis (BE) is defined as a clinical syndrome of recurrent, persistent wet cough and abnormal bronchial dilatation on chest High Resolution Computed Tomography (HRCT) scans. The aims of this study were to characterize the pattern of the trajectories of lung function parameters and to consider the relationship between the lung function and radiological severity according to the modified Reiff score.

Methods: The study retrospectively considered 86 children (46.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic obstructive pulmonary disease (COPD) and other chronic respiratory disorders like cystic fibrosis and alpha-one antitrypsin deficiency share inflammation and progression characteristics, prompting investigations into anti-inflammatory treatments.
  • A systematic review of studies from 2000 onward focuses on the role of protein phosphatase 2A (PP2A) in inflammation, its suppression by smoking, and the potential benefits of its activation in treating COPD.
  • Experts suggest that activating PP2A could be a viable therapy for COPD and related disorders, highlighting promising avenues like repurposing metformin and inhalation methods, although most evidence is still in the experimental stage.
View Article and Find Full Text PDF
Article Synopsis
  • - Chronic airway inflammation is a major factor in bronchiectasis, influenced by neutrophils that release harmful proteins called neutrophil serine proteases (NSPs) in both cystic fibrosis (CF) and non-CF conditions.
  • - There’s an imbalance between NSPs and their counteracting proteins in patients with CF and non-CF bronchiectasis, but effective treatments targeting NSPs are currently lacking.
  • - Even with new CFTR modulator therapies improving outcomes for cystic fibrosis patients, airway inflammation remains a problem, highlighting the need for new treatment strategies focused on managing neutrophilic inflammation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!